Skip to main content
Header logo
  • About us Open link menu
    About us
    • Our Purpose
    • Leadership and Board
    • Scientific Advisory Board
    • ESG
  • Our Science Open link menu
    Our Science
    • Pipeline
    • Clinical trials Open link menu
      Clinical trials
      • BEXMAB
      • MATINS
      • BEXCOMBO
    • Bexmarilimab
  • News Open link menu
    News
    • Press Releases Open link menu
      Press Releases
      • Subscribe to News
    • Behind the Science
    • Media Gallery
    • Blog
  • Investors Open link menu
    Investors
    • Osakeanti
    • Public offering
    • Why Invest in Faron
    • Results & Presentations
    • The Share
    • Event Calendar
    • Shareholder Information
    • Advisers
    • Corporate Governance
    • General Meetings
  • Careers
  • Contact
LSE 71.60GBp -2.10
HEL 71.60GBp -2.10
  • Please fill out this field
  • Facebook Linkedin Twitter Email
Please fill out this field

Tue, 08/29/2023 - 9:00

Interim Results for the H1 2023

Faron´s Interim Results for H1 2023 released on 29 August 2023

Download Faron’s Half Year Financial Report 2023

Webcast

H1 2023 presentation

Quick links

  • About us
  • ESG
  • Financial Calendar
  • Why Invest in Faron

Annual report 2023

Leading the way in breakthrough immunotherapies. Read more in Annual Report 2023.

Download Annual Report

Stay in touch

Keep up to date on social media

Terms of use Privacy Notice Cookie Notice Cookie Settings Sitemap